IL260874A - - Google Patents

Info

Publication number
IL260874A
IL260874A IL26087418A IL26087418A IL260874A IL 260874 A IL260874 A IL 260874A IL 26087418 A IL26087418 A IL 26087418A IL 26087418 A IL26087418 A IL 26087418A IL 260874 A IL260874 A IL 260874A
Authority
IL
Israel
Application number
IL26087418A
Other languages
English (en)
Other versions
IL260874B2 (en
IL260874B1 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL260874A publication Critical patent/IL260874A/en
Publication of IL260874B1 publication Critical patent/IL260874B1/en
Publication of IL260874B2 publication Critical patent/IL260874B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/173Purine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
IL260874A 2016-02-12 2017-02-10 Methods of treatment and prevention of HIV and AIDS IL260874B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662294576P 2016-02-12 2016-02-12
US201662297657P 2016-02-19 2016-02-19
PCT/US2017/017283 WO2017139519A1 (en) 2016-02-12 2017-02-10 Methods for treatment and prophylaxis of hiv and aids

Publications (3)

Publication Number Publication Date
IL260874A true IL260874A (enExample) 2018-09-20
IL260874B1 IL260874B1 (en) 2023-06-01
IL260874B2 IL260874B2 (en) 2023-10-01

Family

ID=58057333

Family Applications (1)

Application Number Title Priority Date Filing Date
IL260874A IL260874B2 (en) 2016-02-12 2017-02-10 Methods of treatment and prevention of HIV and AIDS

Country Status (37)

Country Link
US (4) US10537589B2 (enExample)
EP (1) EP3413897B1 (enExample)
JP (4) JP6810972B2 (enExample)
KR (4) KR20250136420A (enExample)
CN (2) CN113509480A (enExample)
AU (3) AU2017217656B2 (enExample)
BR (1) BR112018016349A2 (enExample)
CA (1) CA3013473C (enExample)
CL (1) CL2018002150A1 (enExample)
DK (1) DK3413897T3 (enExample)
DO (1) DOP2018000183A (enExample)
EA (1) EA201891814A1 (enExample)
ES (1) ES2953535T3 (enExample)
FI (1) FI3413897T3 (enExample)
GE (1) GEP20217231B (enExample)
HR (1) HRP20230935T1 (enExample)
HU (1) HUE063532T2 (enExample)
IL (1) IL260874B2 (enExample)
JO (1) JOP20170038B1 (enExample)
LT (1) LT3413897T (enExample)
MD (1) MD3413897T2 (enExample)
MX (3) MX390604B (enExample)
MY (1) MY197090A (enExample)
NI (1) NI201800083A (enExample)
NZ (1) NZ745065A (enExample)
PH (1) PH12018501712A1 (enExample)
PL (1) PL3413897T3 (enExample)
PT (1) PT3413897T (enExample)
RS (1) RS64448B1 (enExample)
SG (1) SG11201806783WA (enExample)
SI (1) SI3413897T1 (enExample)
SV (1) SV2018005733A (enExample)
TN (1) TN2018000267A1 (enExample)
TW (2) TW202417010A (enExample)
UA (1) UA126375C2 (enExample)
WO (1) WO2017139519A1 (enExample)
ZA (1) ZA201805073B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
WO2019016679A1 (en) * 2017-07-18 2019-01-24 Viiv Healthcare Company Combination drug therapy
WO2020007070A1 (zh) * 2018-07-02 2020-01-09 河南真实生物科技有限公司 4'-取代核苷的晶型、制备和应用
US12005072B2 (en) 2018-07-17 2024-06-11 Merck Sharp & Dohme Llc HIV drug combination for increasing barrier against resistance
BR112021012133A8 (pt) * 2018-12-20 2023-04-11 Merck Sharp & Dohme Forma 1 anidra cristalina de 4'-etinil-2-fluoro-2'-desoxiadenosina, forma 4 anidra cristalina de 4'-etinil-2-fluoro-2'-desoxiadenosina, e, composição farmacêutica
AU2020211600A1 (en) 2019-01-25 2021-07-22 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
MA55200A (fr) * 2019-03-06 2022-01-12 Glaxosmithkline Ip No 2 Ltd Composés utiles dans la thérapie du vih
CN114502175B (zh) 2019-07-27 2025-02-25 腾盛博药生物科技有限公司 腺苷衍生物和包含其的药物组合物
WO2023196832A2 (en) * 2022-04-06 2023-10-12 Brii Biosciences, Inc. Pharmaceutical composition and method for treatment of human immunodeficiency virus infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU722214B2 (en) * 1995-06-07 2000-07-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis B virus activity
CA2514466C (en) 2003-02-19 2015-05-26 Yale University Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
US8513205B2 (en) * 2008-04-11 2013-08-20 Yale University Potent chimeric NRTI-NNRTI bifunctional inhibitors of HIV-1 reverse transcriptase
WO2012099630A1 (en) * 2011-01-20 2012-07-26 University Of Rochester Compositions and methods for treating or preventing a retrovirus infection
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
WO2017053216A2 (en) 2015-09-23 2017-03-30 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
EP3454868A4 (en) * 2016-05-12 2019-12-18 Merck Sharp & Dohme Corp. ACTIVE SUBSTANCE RELEASE SYSTEM FOR RELEASING VIRUZIDS
US20190388336A1 (en) * 2016-06-20 2019-12-26 Merck Sharp & Dohme Corp. Drug Delivery System for the Delivery of Antiviral Agents
WO2019016679A1 (en) * 2017-07-18 2019-01-24 Viiv Healthcare Company Combination drug therapy
CR20220053A (es) * 2019-08-13 2022-04-20 Merck Sharp & Dohme Sistema de administración de medicamentos para la administración de agentes antivíricos
EP4146302A4 (en) * 2020-05-05 2024-05-22 Merck Sharp & Dohme LLC DRUG DELIVERY SYSTEM FOR DELIVERY OF ANTIVIRAL AGENTS AND CONTRACEPTIVES
WO2022046578A1 (en) * 2020-08-25 2022-03-03 Merck Sharp & Dohme Corp. Injectable depot compositions for the delivery of antiviral agents

Also Published As

Publication number Publication date
JP6810972B2 (ja) 2021-01-13
JP7021314B2 (ja) 2022-02-16
JP2019504857A (ja) 2019-02-21
HUE063532T2 (hu) 2024-01-28
KR20250136420A (ko) 2025-09-16
AU2017217656B2 (en) 2020-01-30
US20180055867A1 (en) 2018-03-01
AU2020202866A1 (en) 2020-05-21
AU2020202866B2 (en) 2022-04-07
CA3013473C (en) 2021-10-26
MX2022002925A (es) 2023-02-10
AU2017217656A1 (en) 2018-08-23
EA201891814A1 (ru) 2019-01-31
EP3413897B1 (en) 2023-06-14
US20220331350A1 (en) 2022-10-20
DOP2018000183A (es) 2018-12-31
AU2022201686A1 (en) 2022-03-31
JP2024001206A (ja) 2024-01-09
HK1257347A1 (en) 2019-10-18
JP7559175B6 (ja) 2024-10-22
CA3013473A1 (en) 2017-08-17
PH12018501712A1 (en) 2019-05-15
MD3413897T2 (ro) 2023-11-30
DK3413897T3 (da) 2023-09-18
KR20210049201A (ko) 2021-05-04
US20250073254A1 (en) 2025-03-06
IL260874B2 (en) 2023-10-01
JOP20170038B1 (ar) 2021-08-17
ES2953535T3 (es) 2023-11-14
SV2018005733A (es) 2018-12-14
RS64448B1 (sr) 2023-09-29
CN113509480A (zh) 2021-10-19
NZ784982A (en) 2025-03-28
NZ745065A (en) 2023-11-24
CN108697727A (zh) 2018-10-23
TW201731514A (zh) 2017-09-16
JP2021001189A (ja) 2021-01-07
US11337991B2 (en) 2022-05-24
JP7559175B2 (ja) 2024-10-01
SG11201806783WA (en) 2018-09-27
SI3413897T1 (sl) 2023-11-30
TWI822652B (zh) 2023-11-21
KR102317570B1 (ko) 2021-10-25
PL3413897T3 (pl) 2023-10-02
LT3413897T (lt) 2023-08-25
HRP20230935T1 (hr) 2023-11-24
TW202417010A (zh) 2024-05-01
US12171776B2 (en) 2024-12-24
NI201800083A (es) 2018-10-05
MY197090A (en) 2023-05-24
US10537589B2 (en) 2020-01-21
CL2018002150A1 (es) 2018-12-14
GEP20217231B (en) 2021-03-25
TN2018000267A1 (en) 2020-01-16
WO2017139519A1 (en) 2017-08-17
MX390604B (es) 2025-03-20
IL260874B1 (en) 2023-06-01
ZA201805073B (en) 2019-05-29
MX2022002924A (es) 2022-12-15
UA126375C2 (uk) 2022-09-28
US20200101098A1 (en) 2020-04-02
AU2022201686B2 (en) 2024-08-08
BR112018016349A2 (pt) 2018-12-26
JP2022062170A (ja) 2022-04-19
FI3413897T3 (fi) 2023-08-25
EP3413897A1 (en) 2018-12-19
MX2018009763A (es) 2018-11-29
PT3413897T (pt) 2023-08-28
KR20180108815A (ko) 2018-10-04
KR20220126787A (ko) 2022-09-16

Similar Documents

Publication Publication Date Title
CH714036A1 (enExample)
CN303538881S (enExample)
CN303539089S (enExample)
CN303536629S (enExample)
CN303536529S (enExample)
CN303536241S (enExample)
CN303536230S (enExample)
CN303672216S (enExample)
CN303669367S (enExample)
CN303536221S (enExample)
CN303656105S (enExample)
CN303641860S (enExample)
CN303627593S (enExample)
CN303626734S (enExample)
CN303594604S (enExample)
CN303549683S (enExample)
CN303549020S (enExample)
CN303546509S (enExample)
CN303539447S (enExample)
CN303539429S (enExample)
CN303539396S (enExample)
CN303539345S (enExample)
CN303539312S (enExample)
CN303536219S (enExample)
CN303539116S (enExample)